Cargando…
Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
Hyponatremia is the most common electrolyte abnormality seen in clinical practice. Most cases of euvolemic or hypervolemic hyponatremia involve arginine vasopressin (AVP). AVP leads to a concentrated urine and negative free water clearance. Given this primary role of AVP, antagonizing its effect thr...
Autores principales: | Bowman, Brendan T, Rosner, Mitchell H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712664/ https://www.ncbi.nlm.nih.gov/pubmed/23874242 http://dx.doi.org/10.2147/CE.S36744 |
Ejemplares similares
-
Tolvaptan and its potential in the treatment of hyponatremia
por: Dixon, Megan B, et al.
Publicado: (2008) -
Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells
por: Di Mise, Annarita, et al.
Publicado: (2019) -
Exercise-Associated Hyponatremia: 2017 Update
por: Hew-Butler, Tamara, et al.
Publicado: (2017) -
Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy
por: Romanovsky, Adam, et al.
Publicado: (2011) -
Conivaptan: Evidence supporting its therapeutic use in hyponatremia
por: Li-Ng, Melissa, et al.
Publicado: (2010)